AZILECT® + Placebo

ApprovedUNKNOWN

2 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Drug-naïve Patients With Parkinson's Disease

Conditions

Drug-naïve Patients With Parkinson's Disease, Apathy

Trial Timeline

Jun 1, 2013 → Mar 1, 2015

NCT ID

NCT01765257

About AZILECT® + Placebo

AZILECT® + Placebo is a approved stage product being developed by Lundbeck for Drug-naïve Patients With Parkinson's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT01765257. Target conditions include Drug-naïve Patients With Parkinson's Disease, Apathy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01765257	Approved	UNKNOWN	Jun 1, 2013	Mar 1, 2015	Drug-naïve Patients With Parkinson's Disease